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Abstract
Background and objectives: Gastrinomas are the most prevalent functioning neuroen-
docrine tumors (NET) in multiple endocrine neoplasia type 1 (MEN1). Guidelines suggest
medical therapy in most patients, but surgery may be considered in a subgroup. Currently,
factors to guide management are necessary. This population‐based cohort study assessed
prognostic factors of survival in patients with MEN1‐related gastrinomas.
Methods: Patients with MEN1 having gastrinomas were identified in the Dutch
MEN1 database from 1990 to 2014 based on fasting serum gastrin (FSG) levels and/
or pathology. Predictors of overall survival were assessed using Cox regression.
Results: Sixty‐three patients with gastrinoma (16% of the MEN1 population) were
identified. Five‐ and 10‐year overall survival rates were 83% and 65%, respectively.
Prognostic factors associated with overall survival were initial FSG levels ≥20x upper
limit of normal (ULN) (hazard ratio [HR], 6.2 [95% confidence interval, 1.7‐23.0]),
pancreatic NET ≥2 cm (HR 4.5; [1.5‐13.1]), synchronous liver metastases (HR 8.9;
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Abbreviations: CI, Confidence interval; CT, Computed tomography; DMSG, Dutch MEN Study Group; dpNET, Duodenopancreatic neuroendocrine tumor; ENETS, European Neuroendocrine
Tumor Society; EUS, Endoscopic ultrasonography; FSG, Fasting serum gastrin; HR, Hazard ratio; MEN1, Multiple endocrine neoplasia type 1; MRI, Magnetic resonance imaging; NET,
Neuroendocrine tumor; NF‐pNET, Nonfunctioning pancreatic neuroendocrine tumor; OS, Overall survival; pHPT, Primary hyperparathyroidism; pNET, Pancreatic neuroendocrine tumor; PPI,
Proton pump inhibitor; SD, Standard deviation; ULN, Upper limit of the normal of the reference range; UMC, University Medical Center.
[2.1‐36.7]), gastroduodenoscopy suspicious for gastric NETs (HR 12.7; [1.4‐115.6]),
and multiple concurrent NETs (HR 5.9; [1.2‐27.7]).
Conclusion: Life expectancy of patients with MEN1 gastrinoma is reduced. FSG levels
and pancreatic NETs ≥2 cm are prognostic factors. FSG levels might guide
surveillance intensity, step‐up to additional diagnostics, or provide arguments in
selecting patients who might benefit from surgery.
K E YWORD S
multiple endocrine neoplasia type 1, neuroendocrine tumor, oncology, Zollinger‐Ellison
syndrome
1 | INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal
dominant disorder caused by a mutation in the MEN1 gene leading to
a combination of endocrine and nonendocrine tumors.1 Duodeno-
pancreatic neuroendocrine tumors (dpNETs) are a common manifes-
tation and have a prevalence of 56% in the Dutch MEN1 population.2
Gastrinomas are the most frequently encountered functioning
dpNETs and occur in approximately 30% of patients with MEN1.3
These tumors produce gastrin which induces gastric acid hypersecre-
tion and subsequently leads to ulcerative peptic disease and
gastrointestinal bleeding, known as the Zollinger‐Ellison syndrome.4
MEN1‐related gastrinomas are generally located in the duodenal
submucosa and are rarely found in the pancreas.5,6 Duodenal
gastrinomas are often small (<1 cm), multiple and accompanied by
pancreatic neuroendocrine tumors (pNETs).6 Approximately 70% to
80% of surgically treated patients have lymph node metastases, and
10% present with synchronous liver metastases.7,8
Gastric acid hypersecretion‐related complications used to be the
leading cause of death in patients with MEN1 having gastrinomas
before the widespread use of proton pump inhibitors (PPIs).9,10
Nowadays, compared with the general population, patients with
MEN1 have a seriously decreased life expectancy mainly caused by
malignant dpNETs.2 However, the reported prognosis of patients
with MEN1 gastrinoma varies widely.8,11-13 In the French cohort,
studied from 1956 to 2005, gastrinomas have been reported as an
independent risk factor for death.9 Actual data on MEN1 gastrinoma
survival are scarce and survival rates are difficult to interpret since
patients are diagnosed and treated differently among studies. In
addition, the understanding that MEN1 gastrinomas mostly originate
in the duodenum instead of the formerly assumed pancreatic origin,
emphasizes the need for new studies. Besides, data regarding the
long‐term natural history are important, because guidelines suggest
symptomatic management using PPIs in the majority of patients.14,15
Nevertheless, the only potentially curative oncological treatment
remains surgery. Pancreaticoduodenectomy offers the possibility to
achieve a biochemical cure for MEN1‐related duodenal gastrino-
mas.8 However, controversies exist regarding the timing and the
extent of surgery, considering the unpredictable tumor course and
morbidity associated with extensive surgery.14,15 Therefore, the
necessity of prognostic factors to guide therapy has recently been
underscored.16 Since gastrinomas are hormone producing tumors,
we hypothesized that, besides known dpNET‐related prognostic
factors such as pNET size and liver metastases, gastrin levels might
predict survival in this population.17 Therefore the present study
aims to assess prognostic factors and survival in patients with
MEN1 having gastrinomas.
2 | MATERIALS AND METHODS
2.1 | Study design
Patients were selected from the national Dutch MEN1 database from
the DutchMEN Study Group (DMSG).18 Patients with MEN1 aged
16 years and older and under treatment in one of the eight
University Medical Centers (UMCs) are included. In each center,
patients were identified by reviewing hospital databases of medical
conditions and diseases. MEN1 diagnosis was established according
to the guidelines.14 Over 90% of the Dutch MEN1 population is
included. Clinical and demographic data were collected longitudinally
every quarter from 1990 to 2014 by standardized medical record
review, according to a predefined protocol. The protocol was
approved by the Medical Ethics Committees of all UMCs.
2.2 | Patient selection
The diagnosis of gastrinomas in patients with MEN1 was challenging,
since the reference standard, provocative tests using secretin, is not
widely available and routine measurements of basal acid output at
gastroduodenoscopy were not routinely performed. Therefore, based
on stringent criteria we aimed to identify those patients of whom we
were confident of having gastrinomas, also using subsequently
elevated fasting serum gastrin (FSG) levels. Gastrinoma diagnosis
was based on (a) pathology reports of gastrin immunohistochemistry
positive tumors or (b) elevated FSG levels, or (c) gastroduodenoscopy
suspicious for gastrinoma, or a combination of these. Serum gastrin
reference values were obtained from all UMCs over the study period.
FSG levels were calculated as a factor of the upper limit of normal
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(ULN) of the reference values. Gastrinoma diagnosis was considered
certain when FSG levels were increased more than a 10‐fold of ULN
(regardless of PPI use) or probable when FSG measurements were
elevated consecutively (a) more than a two‐fold of ULN (without PPI)
without consecutive FSG levels <2x ULN during follow‐up or (b) more
than a five‐fold (under PPI) without consecutive FSG levels <5x ULN
during follow‐up, without surgery or the start of systemic antitumor
therapy (Table S1). Pathological gastrinoma diagnosis was estab-
lished if immunohistochemistry of tumor tissue stained positive for
gastrin, in the presence of hypergastrinemia.
2.3 | Clinical definitions
The date of gastrinoma diagnosis was based on the date of the
pathology report or on the date of the first FSG measurement
fulfilling one of the diagnostic criteria. For nongastrinoma patients
the date of the first FSG measurement was used. FSG levels at the
time of gastrinoma diagnosis were regarded as initial FSG levels for
further analysis.
Patients were categorized as a pathological or a biochemical
diagnosis in line with whichever diagnosis came first.
Conventional imaging reports of computed tomography (CT),
magnetic resonance imaging (MRI), endoscopic ultrasonography
(EUS), or gastroduodenoscopy were reviewed for lesions suspicious
for duodenal NETs and suspicious abdominal lymph nodes. Data from
imaging reports up to 1 year before or after the gastrinoma diagnosis
were extracted. Gastroduodenoscopies were also interpreted for
gastric NETs. Lesions considered suspicious included visible tumor,
polyposis, and small nodules. Gastritis and hypergastrinemia‐related
complications were not considered as NET if there was no lesion
suspicious for gastrinoma.
Liver metastases were defined as (a) pathologically proven or (b)
radiologically confirmed liver metastases. Radiology was considered
positive if consecutive CT or MRI reports described suspicious liver
lesions. An MEN1 expert panel, blinded to patient identity, decided
most likely origin of the liver metastases. The presence of
synchronous liver metastases was studied as prognostic factor,
regardless of origin.
Deaths caused by MEN1 manifestations and MEN1‐related
therapy were considered as MEN1 related. Other causes of death
were regarded as non‐MEN1 related.2
MEN1‐related NETs at the moment of gastrinoma diagnosis were
diagnosed according to pathology reports.2 If no pathology reports
were available, imaging results were used for diagnosis as previously
described.19 Gastric NETs were also diagnosed using gastroduode-
noscopies. The size of the largest pNET on conventional imaging was
used for further analysis.
2.4 | Treatment
Patients were treated medically by PPIs to prevent acid‐related
complications by somatostatin analogs or surgically to prevent
metastatic disease. Treatment regimen was decided by the treating
TABLE 1 Patient and disease characteristics at moment of
gastrinoma diagnosis
Overall patients
(n = 63)
Age, mean [SD] 51 [13]
Gender
Male (%) 29 (46%)
Female (%) 34 (54%)
MEN1‐associated tumors at the moment of
gastrinoma diagnosis
Pancreatic NET 33 (52%)
Gastric NET 7 (11%)
Lung NET 5 (8%)
Thymic NET 0
Gastrinoma diagnosis
Pathological only 7 (11%)
Biochemical and pathological confirmation 15 (24%)
Biochemical only 40 (64%)
Imaging suspect for gastrinoma with elevated
FSG levels
1 (2%)
Basis of biochemical gastrinoma diagnosis
1 × >10x ULN 45 (71%)
2 × >2x ULN without PPI or >5x ULN with
PPI
10 (16%)
FSG levels not fulfilling above criteria 8 (13%)
Fasting serum gastrin factor of ULN at
diagnosis, median [range]**
Overall (n = 61) 9.5 [0.5‐412.3]
No PPI, no somatostatin analogs (n = 21) 7.2 [1.4‐137.1]
Under PPI (n = 37) 9.64 [1.1‐412.3]
Under somatostatin analogs (n = 2) 45.7 [0.5‐90.9]
Under PPI and somatostatin analogs (n = 1) 19.2
Fasting serum gastrin factor of ULN at
diagnosis, median [range]
Biochemical diagnosis (n = 53) 11.0 [2.0‐412.3]
Pathological diagnosis (n = 7) 2.1 [0.5‐3.4]
Year of diagnosis
Before 2007 31 (49%)
2007 and after 32 (51%)
Imaging suspicious for NET duodenum***
Yes 15/5 (26%)
No 41/57 (74%)
Gastroduodenoscopy suspicious for NET
duodenum****
Yes 13/25 (52%)
No 12/25 (48%)
Patients with positive gastroduodenoscopy
suspicious for NET duodenum
Solitary lesion 5/13 (38%)
Multiple lesions 8/13 (62%)
Size duodenal abnormalities in mm, median
[range] (n = 9)
7.5 [3‐20]
Gastroduodenoscopy suspicious for NET
stomach
Yes 7/25 (28%)
No 18/25 (72%)
(Continues)
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physician together with the patient after multidisciplinary team
discussion.
2.5 | Outcome measures
The primary outcomes were 5‐ and 10‐year overall survival (OS).
Possible prognostic factors at gastrinoma diagnosis were analyzed
for influence on OS. The date of death or date of last follow‐up was
used for analysis.
2.6 | Statistical analysis
Descriptive statistics were reported as mean (standard deviation [SD]) or
median (range), as appropriate, or as numbers (percentages). Differences
in means were tested using t tests. Survival curves were plotted
according to the Kaplan‐Meier method and survival probabilities were
obtained.20 Follow‐up time started at the moment of gastrinoma
diagnosis. Kaplan‐Meier curves were plotted for patients with MEN1
gastrinoma against nongastrinoma patients from the database. Concern-
ing the difference age, patients with gastrinoma were 1:1 age and gender
matched with a nongastrinoma patient. The log‐rank test was used for
Kaplan‐Meier curve comparison.
Prognostic factors for OS were assessed using uni‐ and multi-
variable Cox proportional hazard regression providing hazard ratios
(HR’s) with 95% confidence intervals (95% CIs) ties were handled
using the exact method. Cox proportional hazard assumptions were
formally tested and graphically assessed using scaled Schoenfeld
residual plots; the assumptions were not violated. Prognostic factors
were adjusted for age, since age is associated with OS.11 Continuous
variables were dichotomized based on previous literature; pNET size
on conventional imaging to <2.0 cm and ≥2.0 cm, and FSG levels at
gastrinoma diagnosis to <20x ULN and ≥20x ULN.10,11
Since surgery might reduce FSG levels, subgroup analysis for the
prognostic value of FSG levels was performed in nonsurgically
managed patients. Furthermore, subgroup analysis was conducted in
patients without liver metastases at gastrinoma diagnosis. All test
were performed two‐tailed. P‐values <.05 were considered statisti-
cally significant. Statistical analysis was performed using SPSS
version 25.0 (IBM Corp, New York), RStudio version 1.0.143
(RStudio, Inc., Boston, MA); figures were constructed using Graphpad
Prism version 7.02 (GraphPad Software Inc, California).
3 | RESULTS
3.1 | DMSG database
A total of 396 patients were identified, of whom 357 (90%) had FSG
measurements at least once between 1990 and 2014. The median
number of measurements was 7 (1‐54) per patient. Hypergastrinemia
TABLE 1 (Continued)
Overall patients
(n = 63)
Suspicious lymph nodes on imaging at
gastrinoma diagnosis
Yes 12 (19%)
No 51 (81%)
Liver metastases at diagnosis***** 5 (8%)
Gastrinoma 3
NF‐pNET 1
Gastrinoma or NF‐pNET 1
Abbreviations: FSG, fasting serum gastrin; NET, neuroendocrine tumor;
NF‐pNET, nonfunctioning pancreatic neuroendocrine tumor; PPI, proton
pump inhibitor; SD, standard deviation; ULN, upper limit of normal of the
reference value.
*According to which diagnosis came first.
**FSG levels are reported for subgroups on medical therapy (PPI,
somatostatin analogs or both) at the moment of FSG measurement.
***Imaging suspect for gastrinoma duodenum: abnormalities on computed
tomography (CT), magnetic resonance imaging (MRI), gastroduodeno-
scopy, or endoscopic ultrasonography.
****Gastroduodenoscopy suspicious for NET: visible tumor, polyposis
without another diagnosis and small nodules which could be biopsied.
Possible Zollinger‐Ellison syndrome‐related complications such as peptic
ulcera were not considered as suspected for NET. Gastritis was not
documented as suspect for NET.
*****Origin of liver metastases according to the expert panel.
TABLE 2 Survival and long‐term outcomes of patients with MEN1
gastrinoma
Overall patients
(n = 63)
Follow‐up in years, median [range]* 4.7 [0.25‐23.5]
Overall survival
5‐y, % (95% CI) 83% (68‐92%)
10‐y, % (95% CI) 65% (47‐79%)
Liver metastases** 8 (14%)
Gastrinoma 3
NF‐pNET 2
Gastrinoma or NF‐pNET 1
Thymic NET 1
Unknown origin/unknown if MEN1 dpNET
related
1
Death 17 (27%)
MEN1‐related 11 (65%)
Duodenopancreatic NET related 8
Thymic NET 1
Renal insufficiency caused by pHPT 1
Complication MEN1 pancreatic surgery 1
Non‐MEN1‐related 5 (29%)
Unknown 1 (6%)
Abbreviations: dpNET, duodenopancreatic neuroendocrine tumor; MEN1,
multiple endocrine neoplasia type 1; NF‐pNET, nonfunctioning pancreatic
neuroendocrine tumor; NET, neuroendocrine tumor; pHPT, primary
hyperparathyroidism.
*Follow‐up until death or end of follow‐up.
**Origin of liver metastases is based on the expert panel. Percentage is based
on the group of patients without liver metastases at diagnosis (n = 58).
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was observed in 193 patients (54%), regardless of PPI use. In 114
patients (32%), FSG levels were >1x ULN in the absence of PPI. One
hundred patients (28%) had FSG levels >2x ULN under PPI.
Ten‐fold increased FSG levels were longitudinally observed in
45 patients (13%).
3.2 | Patient characteristics
Demographic and clinical characteristics are described in Table 1.
Sixty‐three patients with gastrinoma (16%) were identified in the
DMSG database with a mean age of 51 years (±13). Fifty‐four
percent were female. Most patients were diagnosed biochemically
(64%) and 15 patients (24%) had a biochemical diagnosis with
histopathological gastrinoma confirmation. In 22 patients (35%)
gastrinomas were histopathologically proven. On the basis of
biochemical criteria, 45 patients (71%) were diagnosed as certain
and 10 (16%) as probable. Median FSG levels at diagnosis were 9.5x
ULN (0.5‐412).
Thirty‐five patients (56%) harbored a concurrent NET at the time
of gastrinoma diagnosis. Thirty‐three patients had a concurrent pNET
(52%). Eight patients had a pNET and concurrent lung or gastric NET.
One patient with a pathologically confirmed gastric gastrinoma also
had a concurrent gastric NET. Five patients (8%) harbored
synchronous liver metastases. For two patients the liver metastases
were pathologically proven; nonfunctioning pNET (NF‐pNET) liver
metastases in one and gastrinoma‐related in another.
Forty‐seven patients (75%) received medical treatment and 16
patients (25%) underwent surgery (Figure S1). Two patients
additionally received peptide receptor radionuclide therapy, of whom
one died during the follow‐up.
3.3 | Long‐term outcomes
Patient outcomes are reported in Table 2. Eight patients (14%)
developed liver metastases after a median follow‐up of 4.5 years
(0.3–23.5 years). Liver metastases of any MEN1‐related manifesta-
tion were confirmed by pathology in three patients, whereas in five
patients the diagnosis and origin were established by the expert
panel. Gastrinoma liver metastases were pathologically confirmed in
one patient. After a follow‐up of 4.7 years, 17 patients (27%) had
died; at a median age of 58 years (33–81 years). Eleven deaths (65%)
were regarded as MEN1 related. Most MEN1‐related deaths (73%)
resulted from dpNET progression. Two patients were lost during the
follow‐up.
3.4 | Survival of patients with MEN1 gastrinoma
OS rates of patients with MEN1 gastrinoma after 5 and 10 years
were 83% and 65%, respectively (Table 2; Figures 1A and S2A). Five
and 10‐year OS rates for patients with MEN1 having FSG
measurements not indicative for a gastrinoma were 93% and 87%,
respectively (Figures 1B and S2B). Patient with gastrinomas were
older than patients without gastrinomas (51 vs 39 years, P < .001).
Ten‐year OS rates were 65% vs 81% for age and gender matched
MEN1 patients without gastrinomas (Figures 1C and S2C).
3.5 | Prognostic factors for OS
Prognostic factors for OS are shown in Table 3. Factors significantly
associated with OS were FSG levels >20x ULN (HR, 6.16; [95% CI,
1.65‐23.02]), pNET ≥2.0 cm on conventional imaging (HR, 4.46; [1.52‐
13.06]), synchronous liver metastases of any origin (HR, 8.86; [2.14‐
36.7]), multiple concurrent NETs (HR, 5.86; [1.24‐27.65]), and
gastroduodenoscopy suspicious for gastric NET (HR, 12.74; [1.40‐
(A)
(B)
(C)
F IGURE 1 Overall survival (OS) of MEN1 gastrinoma patients
(A). OS of MEN1 patients with and without gastrinomas (B). OS of
MEN1 patients with and without gastrinomas (age and gender
matched) (C). MEN1, multiple endocrine neoplasia type 1
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115.6]). After adjusting for age, these factors were significantly
associated with OS.
Initial FSG levels determined prognosis in patients with MEN1
gastrinoma. Ten year OS was more favorable for patients with FSG
<10x ULN compared with patients with FSG ranging from 10 to 20x
ULN and FSG ≥20x ULN (83%, 66%, and 33%, respectively) (Figures 2
and S3). Corresponding HR’s were 2.66 ([0.57‐12.27]; P = .214) for
FSG ranging from 10 to 20x ULN and 6.16 ([1.65‐23.02]; P = .007) for
FSG ≥20x ULN. Comparable results were observed in nonsurgically
managed patients and patients without synchronous liver metastases
(Table 4).
4 | DISCUSSION
Gastrinomas in patients with MEN1 lead to a decreased life
expectancy with 5 and 10‐year OS rates of 83% and 65%,
respectively. Factors associated with decreased OS were initial FSG
levels ≥20x ULN, a pNET ≥2.0 cm on conventional imaging,
synchronous liver metastases, multiple concurrent NETs, and
gastroduodenoscopy suspicious for gastric NET. These factors may
guide clinical decision making in daily practice.
The 10‐year OS rate in our cohort of patients with gastrinoma
was 65% with a median age at death of 58 years. Overall, patients
with MEN1 in the Netherlands have a life expectancy of 73 years.2
We performed subgroup analysis in age and gender matched
controls, also showing a significantly decreased OS of MEN1
gastrinomas. This underscores that age and gender did not influence
this outcome. Previous studies on patients with MEN1 gastrinoma
reported 10‐year survival rates of 88% to 100% regardless of
therapy.7,8,11-13 Several factors could account for the different
survival rates. First, disease‐specific survival is generally higher than
OS.10-12 Second, in the other cohorts also nongastrinoma patients
might have been included because of the method of identifying
gastrinomas. Finally, patient prognosis might be influenced by
treatment regimen. In our cohort, only 25% of the patients under-
went surgery and in a substantial part the duodenum was notT
A
B
L
E
3
(C
o
n
ti
n
u
ed
)
N
D
ea
th
s
O
ve
ra
ll
su
rv
iv
al
p
ro
b
ab
ili
ti
es
U
n
ad
ju
st
ed
H
R
(9
5
%
C
I)
,P
‐v
al
u
e
A
ge
‐a
d
ju
st
ed
H
R
(9
5
%
C
I)
,P
‐v
al
u
e
5
‐y
1
0
‐y
Su
sp
ic
io
u
s
ly
m
p
h
n
o
d
es
o
n
im
ag
in
g
at
ga
st
ri
n
o
m
a
d
ia
gn
o
si
s
N
o
5
1
1
5
8
0
%
6
4
%
1
(R
ef
.c
at
.)
1
(R
ef
.c
at
.)
Y
es
1
2
2
1
0
0
%
6
7
%
0
.8
8
(0
.2
0
‐3
.9
5
),
P
=
.8
6
8
1
.1
6
(0
.2
4
‐5
.5
2
),
P
=
.8
5
2
Li
ve
r
m
et
as
ta
se
s
at
ga
st
ri
n
o
m
a
d
ia
gn
o
si
s
N
o
5
8
1
4
8
8
%
6
9
%
1
(R
ef
.c
at
.)
1
(R
ef
.c
at
.)
Y
es
5
3
2
5
%
‐
8
.8
6
(2
.1
4
‐3
6
.7
),
P
=
.0
0
3
6
.5
6
(1
.4
2
‐3
0
.3
8
),
P
=
.0
1
6
A
b
b
re
vi
at
io
n
s:
H
R
,h
az
ar
d
ra
ti
o
;
N
A
,n
o
t
ap
p
lic
ab
le
;
N
E
T
,n
eu
ro
en
d
o
cr
in
e
tu
m
o
r;
P
P
I,
p
ro
to
n
p
u
m
p
in
h
ib
it
o
r;
U
LN
,u
p
p
er
lim
it
o
f
th
e
n
o
rm
al
o
f
th
e
re
fe
re
n
ce
va
lu
e.
* C
o
n
ve
n
ti
o
n
al
im
ag
in
g:
m
ag
n
et
ic
re
so
n
an
ce
im
ag
in
g,
co
m
p
u
te
d
to
m
o
gr
ap
h
y,
en
d
o
sc
o
p
ic
u
lt
ra
so
n
o
gr
ap
h
y,
o
r
ga
st
ro
d
u
o
d
en
o
sc
o
p
y
su
sp
ic
io
u
s
fo
r
d
u
o
d
en
al
ga
st
ri
n
o
m
a.
In
o
n
e
ca
se
th
e
ga
st
ro
d
u
o
d
en
o
sc
o
p
y
w
as
su
sp
ic
io
u
s
fo
r
a
ga
st
ri
c
ga
st
ri
n
o
m
a.
F IGURE 2 Overall survival of patients with MEN1 according to
initial fasting serum gastrin levels. MEN1, multiple endocrine
neoplasia type 1
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removed, which is deemed necessary for achieving biochemical cure.8
In addition, patients with synchronous liver metastases were
included in our study. Liver metastases, either NF‐pNET or
gastrinoma related, are associated with survival.7,11,13,17,21 Although
the OS rate was lower, the age of death (58 years) was slightly higher
than in previous series (55‐56 years).10-12
Initial FSG levels were associated OS, also after adjusting for age.
More specifically, OS decreased as FSG levels increased. Ito et al10
described very high FSG levels (>20‐fold elevated) more often in
deceased patients. We observed a significantly increased HR for
death in patients with FSG levels higher than 20x ULN. In line, we
observed a HR of 2.66 and a 10‐year OS of 66% for patients with
FSG levels between 10 and 20x ULN. We believe that the outcomes
of this analysis were not statistically significant due to the low
number of patients and events in this subgroup. NIH series observed
higher FSG levels in patients with an aggressive disease course and in
patients with liver metastases, although no survival analysis was
conducted.7,13 The only study focusing on initial FSG levels and
survival in patients with MEN1 from the NIH, did not find a
significant correlation in MEN1 gastrinoma patients (log rank
P = .068).22 In this study of 53 patients with MEN1 gastrinoma, only
four deaths were observed.22 Compared with our study, in this NIH
series other diagnostic criteria were applied probably influencing the
case mix and, in addition, the study period was a decade earlier.
Pancreatic NET ≥2.0 cm on imaging and liver metastases at
gastrinoma diagnosis were associated with decreased OS. Formerly,
gastrinomas were generally regarded as pNETs causing liver
metastases and death. However, studies including gastrin immuno-
histochemistry and pathological series report the predominant
duodenal origin.5,8,23 Therefore, it can be hypothesized that these
patients have decreased OS because of a concurrent NF‐pNET
≥2.0 cm instead of a pancreatic gastrinoma. Recently, the acceptable
prognosis of NF‐pNETs <2 cm has been highlighted.19,24,25 The
decreased survival of patients with MEN1 having liver metastases
is in line with other studies.11,13 Nevertheless, the exact cause of
death in patients with MEN1 gastrinoma having concurrent large
(NF)‐pNETs remains challenging.
This study is limited by the challenges of gastrinoma diagnosis in
patients with MEN1. Current guidelines recommend the combination
of hypergastrinemia and basal gastric acid hypersecretion
(pH < 2).14,15 Gastrinoma diagnosis frequently differs from these
criteria, because of the lack of gastric pH measurement, the
unavailability of secretin testing and the use of immunohistochem-
istry and imaging as alternatives.26 In daily clinical practice of the
DMSG, gastrinoma diagnosis was complicated by the unavailability of
stimulation tests, no routine measurements of gastric pH and
widespread use of PPI. Because we aimed to study OS and predictors
of OS, we wanted to be sure to select gastrinoma patients only.
Therefore, strict selection criteria were formulated beforehand. Only
11% did not have 10‐fold increased FSG levels nor pathologically
proven gastrinoma. To identify this subgroup of gastrinoma cases, we
reasoned that gastrinomas lead to gradual FSG increases, therefore,
longitudinally collected FSG values were analyzed and patients with
spontaneously decreasing values over time were not regarded as
patients with gastrinoma. FSG measurements in light of the annual
MEN1 screening were performed regardless of PPI use. Although
PPIs are preferably discontinued before FSG measurement, serious
adverse events can occur during sudden interruption.27 Thus, we
believe that for identifying patients with MEN1 gastrinoma including
serial FSG measurements provide a more pragmatic, but still reliable
approach. Other limitations include the retrospective design and the
number of events. Due to the low number of events, extensive
multivariable analysis was impossible and relatively wide confidence
intervals were observed.
The major strength of this study is the population‐based cohort
including >90% of patients with MEN1, with standardized data
collection and long‐term follow‐up. In addition, patients are included
from 1990 onwards, providing more actual survival rates, since
patients with MEN1 are a biochemically screened population and
gastric acid hypersecretion‐related deaths have been rarely reported
over the last two decades.9,10 In the present study, OS was used as
outcome, because OS is more informative and establishing gastrino-
ma‐related deaths (disease‐specific survival) is challenging in the
presence of multiple MEN1 manifestations. Furthermore, this is the
first study to assess prognostic factors, including FSG levels, on OS in
patients with MEN1 using time‐to‐event analysis.
The observed prognostic factors might aid clinicians in selecting
patients with MEN1 having gastrinomas for more intensive follow‐up
regimens or extended localization imaging. Furthermore, knowledge
of prognostic factors and survival can help in selecting those who
TABLE 4 Prognostic value of initial fasting gastrin levels on overall survival (OS)
Overall cohort (n = 63)
Nonsurgically managed patients
(n = 47)
Patients without liver metastases
(n = 58)
10‐y OS HR (95% CI), P‐value 10‐y OS HR (95% CI), P‐value 10‐y OS HR (95% CI), P‐value
Fasting serum gastrin levels
<10x ULN 84% 1 (Ref. cat.) 88% 1 (Ref. cat.) 92% 1 (Ref. cat.)
≥10x ULN & <20x ULN 66% 2.66 (0.57‐12.27),
P = .214
53% 3.67 (0.58‐23.07), P = .165 66% 7.53 (0.82‐69.46), P = .075
≥20x ULN 33% 6.16 (1.65‐23.02),
P = .007
25% 8.40 (1.76‐40.03), P = .008 33% 17.34 (2.15‐140.21),
P = .007
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; ULN, upper limit of the normal of the reference value.
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might benefit from surgery. MEN1 and ENETS guidelines recommend
surgery for patients with MEN1 having pancreatic gastrinomas
>2.0 cm.14,15 Although 52% had a pNET at the moment of gastrinoma
diagnosis, only 19% of all patients in this cohort had pNETs >2.0 cm
on cross‐sectional imaging. Especially, in the coexistence of hyper-
gastrinemia and pNETs ≥2.0 cm, the optimal surgical strategy is hard
to establish. Merging the need for pancreaticoduodenal resections to
achieve biochemical cure on the one hand and the scarcity of data
regarding postoperative complications and long‐term oncological
outcomes after pancreaticoduodenal resections on the other, future
studies should address these topics to come to meaningful advice.28
In conclusion, life expectancy in patients with MEN1 having
gastrinomas is reduced compared with other studies. OS was
associated with initial FSG levels ≥20x ULN, a pNET ≥2.0 cm on
conventional imaging, synchronous liver metastases, multiple con-
current NETs, and gastroduodenoscopy suspicious for gastric NET in
patients with MEN1. OS decreases as FSG levels increase, starting
from ≥10x ULN. Therefore, FSG levels might provide a valuable tool
to guide surveillance intensity, step‐up to additional diagnostic
modalities or provide arguments in selecting those patients who
might benefit from surgery.
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